Skip to main content

Advertisement

SpringerLink
Log in

Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Managing right-sided chronic heart failure (CHF) due to tricuspid regurgitation (TR) remains a clinical challenge. Tolvaptan (TLV), a vasopressin V2 receptor inhibitor, is effective in controlling decompensated HF. However, its effects on right-sided CHF caused by TR are unclear. We sought to clarify the effects of TLV in CHF patients complicated with TR. The cohort consisted of 33 CHF patients with moderate or severe TR and permanent atrial fibrillation, who required hospitalization for HF. We observed 19 patients treated with TLV plus conventional therapies (TLV group) and 14 patients with conventional therapies alone (conventional group). Clinical characteristics, echocardiographic parameters, and laboratory data were investigated. Baseline characteristics were similar between groups. In the TLV group, the severity of TR at admission was 73.7% moderate and 26.3% severe. In the conventional group, these percentages were 85.7% and 14.3%, respectively. During the follow-up, the severity of TR improved in the TLV group (trivial–mild: 52.6%; moderate: 36.8%; severe: 10.5%) (p < 0.01). However, it did not improve in the conventional group (trivial–mild: 21.4%; moderate: 50.0%; severe: 28.6%) (p = 0.08). The diameter of the tricuspid annulus (p < 0.01), basal (p = 0.02), and mid right ventricle (p = 0.04) was reduced at follow-up in the TLV group. Nevertheless, these parameters did not change in the conventional group. Serum creatinine levels were maintained (p = 0.74) in the TLV group, but deteriorated in the conventional group (p = 0.03). TLV reduced right ventricular dimensions and improved TR without deterioration of renal function. Thus, TLV may be a new drug for the treatment of CHF patients with TR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nath J, Foster E, Heidenreich PA (2004) Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 43(3):405–409

    Article  Google Scholar 

  2. Utsunomiya H, Itabashi Y, Mihara H, Berdejo J, Kobayashi S, Siegel RJ, Shiota T (2017) Functional tricuspid regurgitation caused by chronic atrial fibrillation: a real-time 3-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging 10(1):e004897

    Article  Google Scholar 

  3. Eshaghian S, Horwich TB, Fonarow GC (2006) Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97(12):1759–1764

    Article  CAS  Google Scholar 

  4. Markman TM, Plappert T, De Feria AA, Levin M, Amankwah N, Sheth S, Gertz ZM, Schaller RD, Marchlinski FE, Rame JE, Frankel DS (2020) Improvement in tricuspid regurgitation following catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 31(11):2883–2888

    Article  Google Scholar 

  5. Zack CJ, Fender EA, Chandrashekar P, Reddy YNV, Bennett CE, Stulak JM, Miller VM, Nishimura RA (2017) National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol 70(24):2953–2960

    Article  Google Scholar 

  6. Ingraham BS, Pislaru SV, Nkomo VT, Nishimura RA, Stulak JM, Dearani JA, Rihal CS, Eleid MF (2019) Characteristics and treatment strategies for severe tricuspid regurgitation. Heart 105(16):1244–1250

    Article  CAS  Google Scholar 

  7. Kida K, Shibagaki Y, Tominaga N, Matsumoto N, Akashi YJ, Miyake F, Kimura K (2015) Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. Clin Pharmacokinet 54(3):273–284

    Article  CAS  Google Scholar 

  8. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K (2016) Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Card Fail 22(6):423–432

    Article  CAS  Google Scholar 

  9. Takimura H, Hada T, Kawano M, Yabe T, Takimura Y, Nishio S, Nakano M, Tsukahara R, Muramatsu T (2018) A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan. PLoS ONE 13(11):e0207481

    Article  Google Scholar 

  10. Nakamura M, Sunagawa O, Kinugawa K (2018) Tolvaptan improves prognosis in responders with acute decompensated heart failure by reducing the dose of loop diuretics. Int Heart J 59(1):87–93

    Article  CAS  Google Scholar 

  11. Imamura T, Kinugawa K (2019) Update of acute and long-term tolvaptan therapy. J Cardiol 73(2):102–107

    Article  Google Scholar 

  12. Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Imai R, Ozaki Y, Watanabe T, Teraoka T (2017) Safety and efficacy of long-term use of tolvaptan in patients with heart failure and chronic kidney disease. Circ J 81(11):1736–1738

    Article  Google Scholar 

  13. Nakano Y, Mizuno T, Niwa T, Mukai K, Wakabayashi H, Watanabe A, Ando H, Takashima H, Murotani K, Waseda K, Amano T (2018) Impact of continuous administration of tolvaptan on preventing medium-term worsening renal function and long-term adverse events in heart failure patients with chronic kidney disease. Int Heart J 59(1):105–111

    Article  CAS  Google Scholar 

  14. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Shernan S, Thavendiranathan P, Thomas JD, Weissman NJ (2017) Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the american society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance. J Am Soc Echocardiogr 30(4):303–371

    Article  Google Scholar 

  15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J-Cardiovasc Imaging 16(3):233–271

    Article  Google Scholar 

  16. Asmarats L, Puri R, Latib A, Navia JL, Rodes-Cabau J (2018) Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol 71(25):2935–2956

    Article  Google Scholar 

  17. Isomura T, Fukada Y, Miyazaki T, Endo M (2016) Tricuspid surgery for tricuspid regurgitation: review. Gen Thorac Cardiovasc Surg 64(10):577–583

    Article  Google Scholar 

  18. Kotecha D, Piccini JP (2015) Atrial fibrillation in heart failure: what should we do? Eur Heart J 36(46):3250–3257

    CAS  PubMed  PubMed Central  Google Scholar 

  19. McMurray J, Adamopoulos S, Anker S, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez M (2012) ESC committee for practice guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 33(14):1787–1847

    Article  Google Scholar 

  20. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr (2006) Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol-Renal Physiol 290(2):F273–F278

    Article  CAS  Google Scholar 

  21. Takimura H, Muramatsu T, Ito Y, Sakai T (2015) Efficacy and safety of coadministration of tolvaptan and carperitide for acute decompensated heart failure patients. J Clin Exp Cardiolog 6(395):2

    Google Scholar 

  22. Yuan F, Wu Z, Jiang L, Zhou J, Xu L, Liu H, Ma L, Zhai Z, Zhang J (2019) Short-term effects of tolvaptan in tricuspid insufficiency combined with left heart valve replacement-caused volume-overload patients: results of a prospective pilot study. Am J Cardiovasc Drugs 19(2):211–218

    Article  CAS  Google Scholar 

  23. Nonin S, Iwata S, Ito A, Tamura S, Kitada R, Kawai Y, Ishikawa S, Doi A, Hanatani A, Yoshiyama M (2018) Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction. Int J Cardiol Heart Vasc 21:69–73

    PubMed  PubMed Central  Google Scholar 

  24. Tamura Y, Kimura M, Takei M, Ono T, Kuwana M, Satoh T, Fukuda K, Humbert M (2015) Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. Eur Respir J 46(1):283–286

    Article  Google Scholar 

  25. Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N (2018) Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379(24):2297–2306

    Article  Google Scholar 

  26. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ (2018) Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379(24):2307–2318

    Article  Google Scholar 

  27. Sitges M, Vidal B, Delgado V, Mont L, Garcia-Alvarez A, Tolosana JM, Castel A, Berruezo A, Azqueta M, Pare C, Brugada J (2009) Long-term effect of cardiac resynchronization therapy on functional mitral valve regurgitation. Am J Cardiol 104(3):383–388

    Article  Google Scholar 

  28. Bolling SF, Pagani FD, Deeb GM, Bach DS (1998) Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 115(2):381–386 (discussion 387-388)

    Article  CAS  Google Scholar 

  29. Praz F, Grasso C, Taramasso M, Baumbach A, Piazza N, Tamburino C, Windecker S, Maisano F, Prendergast B (2019) Mitral regurgitation in heart failure: time for a rethink. Eur Heart J 40(27):2189–2193

    Article  CAS  Google Scholar 

  30. Grayburn PA, Sannino A, Packer M (2019) Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC 12(2):353–362

    PubMed  Google Scholar 

  31. Kanzaki H, Bazaz R, Schwartzman D, Dohi K, Sade LE, Gorcsan J 3rd (2004) A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. J Am Coll Cardiol 44(8):1619–1625

    Article  Google Scholar 

  32. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417–427

    Article  Google Scholar 

  33. Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE (2011) Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia control. J Am Coll Cardiol 58(14):1474–1481

    Article  Google Scholar 

Download references

Acknowledgements

We thank Ms. Mai Ishihara for her assistance in performing echocardiography.

Funding

None declared.

Author information

Authors and Affiliations

  1. Department of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan

    Tsutomu Murakami, Norihito Nakamura, Makoto Natsumeda, Shingo Matsumoto, Katsuaki Sakai, Yohei Ohno, Norihiko Shinozaki & Yuji Ikari

  2. Department of Cardiology, Kindai University Faculty of Medicine, Osaka, Japan

    Gaku Nakazawa

Authors
  1. Tsutomu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihito Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Natsumeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shingo Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katsuaki Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yohei Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gaku Nakazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Norihiko Shinozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuji Ikari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuji Ikari.

Ethics declarations

Conflict of interest

The authors declare that no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murakami, T., Nakamura, N., Natsumeda, M. et al. Impact of tolvaptan on improvement of tricuspid regurgitation and right ventricular dimension in patients with right-sided heart failure. Heart Vessels 37, 1153–1161 (2022). https://doi.org/10.1007/s00380-021-02014-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-021-02014-7

Keywords

Search

Navigation